Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 1980-1990

  Jin, Ying ^a   Sun, Yan ^a   Shi, Xun ^a   Zhao, Jun ^a   Shi, Lei ^a   Hong, Wei ^a   Yu, Xinmin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

docetaxel monotherapy; docetaxel based doublet; non small cell lung cancer; second line therapy

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; DOCETAXEL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; SELUMETINIB; VANDETANIB; ANTINEOPLASTIC AGENT; TAXOID;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; DIARRHEA; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; RETREATMENT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RETREATMENT; TAXOIDS; THROMBOCYTOPENIA;

EID: 84917710708     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.08.015     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Chheang S, Brown K. Lung cancer staging: Clinical and radiologic perspectives. Semin Intervent Radiol. 2013;30:99-113.
3. Gutierrez A, Suh R, Abtin F, et al. Lung Cancer screening. Semin Intervent Radiol. 2013;30:114-120.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995;311:899-909.
5. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol. 1993;11:1866-1872.
6. Scheff RJ, Schneider BJ. non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Intervent Radiol. 2013;30:191-198.
7. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;7:6251-6266.
8. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol. 1997;24:455-462.
9. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
10. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354-2362.
11. Qi WX, Shen Z, Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2012;69:99-106.
12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
14. Sutton AJ, Abrams KR, Jones DR, Sheldon TR. Methods for meta-analysis in medical research. Wiley, Chichester, 2000.
15. Belvedere O, Follador A, Rossetto C, et al. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). Eur J Cancer. 2011;47:1653-1659.
16. Gebbia V, Gridelli C, Verusio C, et al. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer. 2009;63:251-258.
17. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11:619-626.
18. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2007;25:4270-4277.
19. Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14:38-47.
20. Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial. Lancet Oncol. 2013;14:1326-1336.
21. Lin Q, Meng FJ, Liu Y, et al. Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study. Oncol Lett. 2012;3:761-766.
22. Pallis AG, Agelaki S, Agelidou A, et al. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic nonsmall cell lung cancer. BMC Cancer. 2012;10:633.
23. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol. 2005;16:294-299.
24. Segawa Y, Kiura K, Hotta K, et al. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. J Thorac Oncol. 2010;5:1430-1434.
25. Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: Results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 2009;20:835-841.
26. Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer. 2005;92:15-20.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint-preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89:873-880.
28. Azzoli CG, Temin S, Giaccone G. Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract. 2012;68:63-66.
29. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
30. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525-1531.
31. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bavacizumab for non-smallcell lung cancer. N Engl J Med. 2006;355:2542-2550.
32. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552.
33. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1. J Clin Oncol. 2004;22:777-784.
34. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol. 2004;22:785-794.
35. Gumerlock PH, Pryde BJ, Kimura T. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma. Proc Am Soc Clin Oncol. 2003;22: (Abstr 2661).
36. Spiridonidis CH, Laufman LR, Carman L, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial. Ann Oncol. 2001;12:89-94.
37. Kosmas C, Tsavaris N, Vadiaka M, et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with non-small cell lung carcinoma who fail prior paclitaxel plus platinum regimens. Cancer. 2001;92:2902-2910.
38. Nadella P, Shapiro C, Otterson GA, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol. 2002;20: 2616-2623.
39. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
40. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.